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Background: Anorexia Nervosa (AN) destroys developmentally important early years of many young people and
knowledge is insufficient regarding course, treatment outcome and prognosis. Only a few naturalistic studies have
been conducted within the field of eating disorder (ED) research. In this naturalistic study we included adolescents
with AN or subthreshold AN treated in outpatient care, and the overall aim was to examine sample characteristics
and treatment outcome. Additional aims were to examine potential factors associated with remission as an outcome
variable, and possible differences between three time periods for treatment onset.
Methods: Participants were identified through the Swedish national quality register for eating disorder treatment
(SwEat), in which patients are registered at treatment onset and followed up once a year until end of treatment (EOT).
Inclusion criteria were: medical or self-referral to one of the participating treatment units between 1999 and
2014, 13–19 years of age at initial entry into SwEat and diagnosed with AN or subthreshold AN. The total
sample consisted of 3997 patient from 83 different treatment units.
Results: The results show that 55% of the participants were in remission and approximately 85% were within
a healthy weight range at EOT. Of those who ended treatment according to plan, 70% were in remission and
90% within a healthy weight range. The average treatment duration was approximately 15 months. About
one third of the patients terminated treatment prematurely, which was associated with a decreased chance
of achieving remission. Remission rates and weight recovery increased over time, while treatment duration
decreased. Considering treatment outcome, the results did not show any differences between patients with
AN or subthreshold AN.
Conclusions: The present study shows a relatively good prognosis for adolescent patients with AN or subthreshold
AN in routine care and the results indicate that treatment for adolescents with ED in Sweden has become
more effective over the past 15 years. The results of the present study contribute to the scope of treatment
research and the large-scale naturalistic setting secures the generalizability to a clinical environment. However,
more research is needed into different forms of evidence, new research strategies and diversity of treatment approaches.
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This study is one of few studies within the field of eating
disorder (ED) research that is conducted in a natural
treatment setting. In this study we included adolescents
with Anorexia Nervosa (AN) or comparable symptoms
treated in outpatient care, and the overall aim was to
examine the characteristics of the sample and treatment
results. Additional aims were to examine possible treat-
ment factors that could be associated with being free
from an ED diagnosis at end of treatment (EOT), and
possible differences between three time periods for start
of treatment. Participants were identified through the
Swedish national quality register for eating disorder
treatment (SwEat) and a total of 3997 patients from 83
different treatment units were included. The results
show that 55% of the participants were free from an ED
diagnosis at EOT and about 85% were within a healthy
weight range. The results show no differences between
patients with AN or with comparable symptoms, but ter-
minating treatment prematurely imply a decreased chance
of achieving remission. The results indicate that treatment
has become more effective over the past 15 years.
Background
Anorexia Nervosa (AN) is a severe form of eating disorder
(ED) that is costly, both in terms of personal suffering and
health economy on an individual and societal level, and it
destroys developmentally important early years for many
adolescent girls and boys [1, 2]. Although people of all
ages are affected, AN often has its onset during adoles-
cence and mainly affects girls between 15 and 19 years
[3–5]. Despite recent advances within the ED research
field, there is still inadequate knowledge about the course,
treatment outcome and prognosis of adolescent AN [6].
Early treatment interventions have been shown to be
important for the best effects [1, 7, 8]. When treatment is
delayed, the risk increases for more severe and prolonged
symptoms [2, 9]. However, the treatment often progresses
slowly [10] and is characterized by high dropout rates
[11]. According to previous studies, this is due to comor-
bidity with other psychiatric diagnoses [1, 7, 12], difficul-
ties in responding to therapy when in starvation [13],
patients’ denial of their problems [1, 7] and unwillingness
to gain weight [14]. It has also been suggested that the
physical and cognitive development that occurs during
adolescence, in addition to major life changes like moving
away from home, make treatment planning complex
[1, 2]. Approximately 20–40% relapse within the first
year after end of treatment (EOT) [15, 16], a rate that
is somewhat lower among adolescents than among
adults [16]. Complete recovery is expected in about
50% of AN cases [8, 17, 18].
Only a few naturalistic studies have been conducted
within the field of adolescent ED, (e.g. [19, 20]).Naturalistic studies can add valuable knowledge about the
impact of experimental results and outcome of various
treatments in real life settings, and about descriptive base-
line data for patients. In this naturalistic study we included
adolescents with AN or subthreshold AN, according to
the Diagnostic and Statistical Manual of Mental Disorders
IV (DSM-IV) [21]. We based this on results from previous
studies, showing that patients with subthreshold AN most
often suffer from symptoms to the same extent as patients
with AN, despite a higher BMI (Body Mass Index, kg/m2)
in general [22–24]. This is also in line with the updated
criteria in Diagnostic and Statistical Manual of Mental
Disorders 5 (DSM-5) [25], in which the definition of AN
has been broadened.
The overall aim of this study was to examine sample
characteristics and treatment outcome in a naturalistic
sample of adolescents with AN or subthreshold AN,
treated in outpatient care. Additional aims were to
examine potential factors associated with remission as
an outcome variable, and possible differences in sample
characteristics and treatment outcome between three
time periods for treatment onset.
Methods
Participants in the present study were identified through
the Swedish national quality register for eating disorder
treatment (SwEat). SwEat is a longitudinal internet-
based quality assurance register, developed in 1999, that
includes all specialist ED units in Sweden and a fair
number of general psychiatric units. A total of 108 units
participated in SwEat between 1999 and 2014. The ob-
jectives of SwEat is to document clinically important key
variables, such as waiting time, treatment duration, dif-
ferent types of treatment interventions (e.g. outpatient,
day patient or inpatient treatment) and treatment out-
come [26]. Information is registered in SwEat when it is
established that the patient has an ED diagnosis, the unit
intends to treat the patient and the patient has given
her/his consent to registration. The patient is initially
registered in SwEat at treatment onset and then followed
up once a year until EOT. Each patient might be initially
registered more than once, since a patient is initially regis-
tered again if terminating treatment and later on entering a
new treatment episode. SwEat includes data from patients
of all ages and both genders. A total of 17611 initial regis-
trations were made in SwEat between 1999 and 2014,
when there was a change in methodology and the original
version of SwEat was revised.
Study sample
All patients who met the following criteria were in-
cluded in the study: medical or self-referral to one of the
participating treatment units between 1999 and 2014,
13–19 years of age at initial entry into SwEat and
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DSM-IV [21], which during the years examined consti-
tuted the basis for diagnoses at Swedish ED units (see
Fig. 1 for a flow chart). The patients were diagnosed by
experienced staff in consultation with multidisciplinary
teams, and at most units on the basis of a structured
interview guide. Since 2008 the Structured Eating Dis-
order Interview (SEDI) has been used at Swedish ED
units [27] and before that the most commonly used
interview guide was the Rating of Anorexia and Bulimia
interview (RAB) [28]. In the present study, we focused
on individuals instead of treatments and therefore
included solely information about the first treatment
episode for patients who had more than one episode
registered. By choosing the first treatment episode, weFig. 1 Flowchart, SwEat registrations of patients 13–19 years during 1999–2included mainly information about patients who entered
treatment for the first time. Excluded were patients who i)
were followed up but had an incomplete follow-up regis-
tration, due for instance to inaccurate data, or ii) were still
in treatment when the data collection was discontinued in
2014.
In the first analysis, when examining sample characteris-
tics at treatment onset, all patients remaining considering
the mentioned criteria above were included. In the second
and third analysis we included only patients who were
registered at EOT as “in remission” or as completed for
other reasons. In the second analysis, these patients were
divided into three groups based on different time periods
for treatment onset; Period 1 (1999–2004), Period 2
(2005–2009) and Period 3 (2010–2014). A total of 83014





Does the patient have symptoms consistent
with a specified or unspecified ED, according
to DSM-IV? (Yes/No)
X
Does the clinic intend to treat the patient?
(Yes/No)
X
Has the patient been informed about SwEat
and given his/her oral consent for registration?
(Yes/No)
X
Civic registration number (YYYY-MM-DD-XXXX,
the last four digits comprise the Swedish social
security number and specify gender)
X X
Date of treatment onset (YYYY-MM-DD) X
The patient’s current ED diagnosis (DSM-IV
Axis I/No current ED)
X X
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42 were specialist ED units. Patients in the present study
received inpatient, day patient and/or outpatient treat-
ment, such as individual psychotherapy, family therapy
and group interventions.
Of the patients in the total sample (n = 3997), 35%
were lost to follow-up in SwEat. Comparisons between
followed up and non-followed up patients regarding
baseline characteristics showed only a few differences
between the two groups, of which the most obvious was
that followed-up patients had more social complications
at treatment onset (15.6% vs 9.9%, p = <.001). Further-
more, the patients lost to follow-up had been ill for
rather longer when entering treatment (2.2 years vs
1.9 years, p = <.001) and were younger at first symptoms
(14.4 years vs 14.7 years, p = <.001).The patient’s age at onset of ED symptoms
(years)
X
The patient’s current weight (kg, to one
decimal)
X X
The patient’s current height (cm, to one
decimal)
X X
Are there one or several factors that clearly
complicate treatment? (Yes, of psychiatric
nature/Yes, of somatic nature/Yes, of social
nature/No)
X
Who referred the patient to the unit? (Patient/
Relative/Other treatment unit or school)
XMeasures
SwEat requires information about the following variables
used in the present study (Table 1).
The registration form contains boxes for each re-
sponse alternative, and the system requires that all
boxes are ticked before the form can be submitted.
Even so, most of the variables have 1–3% missing or
invalid answers.
In the present study the following variables were se-
lected as outcome measures:
What previous contact with the health care
services did the patient have for the eating
disorder? (This is the first contact/Previous
contact of an occasional nature/Previous
treatment)
X
Is the patient living alone or with others? X XRemission
Patients not fulfilling criteria for any ED diagnosis at
follow-up were categorized as being in remission.(Single/With children/With parents/With
partner/Other)
The patient’s employment (Studying/Working/
On sick leave)
X X
Is the treatment finished? (Yes/No) X
If the treatment is finished: What date?
(YY-MM-DD)
X
If the treatment is finished: How did it end?
(In agreement between patient and therapist
/Patient terminated treatment prematurely/
Patient was referred to another treatment
unit/Other reason)
X
1This table only includes data presented in the study. The SwEat registration
contains additional dataWeight status
Height and weight, either measured by a therapist or
self-reported by the patient, were used to calculate
the patients’ BMI at initial registration and follow-up.
Based on the BMI percentile method for calculating
expected body weight, we assessed the patients as
being within a normal or low weight range. This was
done in accordance to a previous study describing
and recommending this method [29] and by using
Swedish reference values for BMI, adjusted for age
and gender [30].Premature termination of treatment
The term is used for patients who do not complete treat-
ment, regardless of reason [31]. In the present study, since
there were no prescribed treatment doses and the length
of treatment was not determined at treatment onset, the
term was used to categorize patients terminating treat-
ment either on their own or their parents’ initiative or due
to referral to another treatment unit.Treatment duration
Treatment duration was measured in months and pos-
sible to calculate for the patients who had a registered
date for their first and last treatment session (n = 1904).
Sick leave
At both initial registration and follow-up, information
on employment is requested and clinicians are asked to
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school. In the present study, we did not differentiate
between patients on full or part-time sick leave.
Statistical analyses
Statistical analyses were carried out using IBM SPSS
Statistics 22. In order to compare variable values be-
tween two different patient groups (e.g. followed up and
non-followed up patients) we used Pearson’s chi-square
test and independent samples t-test. When exploring
possible differences between three time periods we used
Pearson’s Chi-square test and one-way ANOVA, and ana-
lyzed post hoc by examining possible differences between
two groups at one time and by using Scheffe’s post hoc
test. Finally, we conducted logistic and multiple logistic
regressions in order to examine factors associated with
remission as an outcome variable. The regressions were
performed using only those independent variables found
to differ significantly between the groups In remission and
Not in remission. In order to correct for multiple analyses,
we used Bonferroni correction with thresholds set at
p = <.001 throughout the study.
Results
Most patients were adolescent girls who, at the time of
treatment onset, were studying and living at home with
their parents or other relatives (Table 2). Approximately
60% were considered to have a low weight when enter-
ing treatment and almost as many had an AN diagnosis.
One third of the patients had previous experiences of
treatment for ED and complicating social, psychiatric or
somatic factors were registered in more than one thirdTable 2 Total sample characteristics at treatment onset
Total sample
(n = 3997)
Girls (%) 3823 (95.6)
Studying (%) 3574 (89.4)
Living with parents/other relatives (%) 3785 (94.7)
Low weight (%) 2385 (59.7)
AN (%) 2284 (57.1)
Previous ED treatment (%) 1221 (30.5)
Social complications (%) 543 (13.6)
Psychiatric complications (%) 685 (17.1)
Somatic complications (%) 149 (3.7)
Sick leave (%) 265 (6.6)
Referred to treatment by other
treatment unit or school (%)
2424 (60.6)
Age at first symptoms of ED M (SD) 14.6 (1.9)
Age when entering treatment M (SD) 16.6 (1.8)
Illness duration at treatment onset (in years) M (SD) 2.0 (1.8)
M mean, SD standard deviationof the cases, of which most were psychiatric. In a few
cases patients were registered as being on sick leave.
Approximately 60% of the patients had been referred to
treatment by for instance another treatment unit or a
school health service. On average the patients had been
ill for two years when entering treatment. Including only
those entering treatment for the first time (n = 2737)
illness duration was approximately 1.7 years (min = 0,
max = 11.9; SD = 1.6).
Separate analyses of patients who were registered at
EOT as “in remission” or as completed for other reasons,
showed that just over two thirds ended treatment ac-
cording to an initial treatment plan or because they were
in remission. Other patients ended treatment prema-
turely, either on their own or their parents’ initiative (n
= 283, 12.9%) or due to referral to another treatment
unit (n = 350, 15.9%). The average treatment duration
was approximately 15 months (min = 1, max = 135). Just
above 55% of the patients were in remission at EOT and
16% of the patients were still considered to have a low
weight (Table 3). Separate analyses of patients who
ended according to plan (n = 1564) revealed that just
under 70% were in remission at EOT and approximately
10% were considered to have a low weight.
The number of patients who were considered to have
a low weight at treatment onset were lower in period 3
and for each period relatively fewer patients had been
entering treatment with an AN diagnosis. The propor-
tion of patients entering treatment with experiences of
previous ED treatment and social or psychiatric compli-
cations were lower in period 2 and 3. Examination of
treatment outcome revealed that treatment duration had
shortened for each time period. There were also a
reduced number of patients who were considered to
have a low weight at EOT in period 3, and a larger number
of patients in remission.
Patients who terminated treatment prematurely had a
decreased chance of achieving remission (Table 4). Remis-
sion was more likely for patients who entered treatment
in time period 3 compared to period 1. Also, although not
significant at < .001, there was a clear tendency in the
adjusted analyses that longer treatment duration was
positively correlated to remission.
Discussion
This study is one of few that investigates treatment out-
come in a naturalistic setting for adolescents with full or
subthreshold AN. The main results show that 55% of the
participants were rated by clinicians as being in remission
and approximately 85% were within a healthy weight range
at EOT. These results are in line with other naturalistic
studies examining treatment outcome among adolescents
with AN (e.g. [19, 20, 32]). However, some of these studies
are old and/or differ from our study in elementary aspects,
Table 3 Treatment characteristics and treatment outcome among patients with completed treatments; results for total sample and












Age at first ED symptoms M (SD) 14.7 (1.9) 14.6 (1.9) 14.8 (1.8) 14.5 (1.9) .007 1-2 .250
2–3 .007
1–3 .499
Age at treatment onset M (SD) 16.6 (1.8) 16.5 (1.9) 16.6 (1.8) 16.4 (1.8) .071 1-2 .644
2–3 .058
1–3 .511
Referred to treatment by other
treatment unit or school (%)
1374 (62.6) 300 (65.6) 771 (63.2) 303 (58.4) .050 1-2 .363
2–3 .056
1–3 .020
Previous ED treatment (%) 667 (30.4) 199 (43.5) 355 (29.1) 113 (21.8) <.001 1-2 <.001
2–3 .002
1–3 <.001
Social complications (%) 355 (16.2) 103 (22.6) 183 (15.0) 69 (13.3) <.001 1-2 <.001
2–3 .352
1–3 <.001
Psychiatric complications (%) 362 (16.5) 104 (22.9) 189 (15.5) 69 (13.3) <.001 1-2 <.001
2–3 .236
1–3 <.001
Somatic complications (%) 88 (4.0) 23 (5.1) 45 (3.7) 20 (3.9) .440 1-2 .209
2–3 .871
1–3 .362
AN (%) 1240 (56.5) 310 (67.8) 683 (56.0) 247 (47.6) <.001 1-2 <.001
2–3 .001
1–3 <.001
Low weight (%) 1231 (56.1) 281 (61.5) 697 (57.2) 253 (48.7) <.001 1-2 .111
2–3 .001
1–3 <.001




Remission (%) 1220 (55.6) 221 (48.4) 682 (55.9) 317 (61.1) <.001 1-2 .006
2–3 .048
1–3 <.001
Low weight (%) 358 (16.3) 97 (21.3) 196 (16.1) 65 (12.5) .001 1-2 .012
2–3 .057
1–3 <.001
Premature termination of treatment (%) 633 (28.8) 127 (27.8) 357 (29.3) 149 (28.7) .832 1-2 .547
2–3 .808
1–3 .750
Treatment duration (months) M (SD)* 14.8 (11.8) 19.2 (15.8) 14.4 (10.8) 11.4 (7.7) <.001 1-2 <.001
2–3 <.001
1–3 <.001




M mean, SD standard deviation
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β (95% CI) Sign. β (95% CI) Sign.
Previous ED treatment (%) Yes 363 (29.8) 304 (31.2) 0.94 (0.78 1.12) .471 1.02 (0.81 1.28) .873
No 857 (70.2) 671 (68.8) Ref
Psychiatric complications
(onset) (%)
Yes 174 (14.3) 188 (19.3) 0.70 (0.56 0.88) .002 0.84 (0.63 1.10) .204
No 1043 (85.7) 787 (80.7) Ref.
AN (onset) (%) Yes 688 (56.4) 552 (56.6) 0.99 (0.84 1.17) .917 1.05 (0.82 1.34) .727
No 532 (43.6) 423 (43.4) Ref.
Low weight (onset) (%) Yes 670 (54.9) 561 (57.5) 0.90 (0.76 1.07) .219 0.79 (0.62 1.00) .054
No 550 (45.1) 414 (42.5) Ref.
Treatment duration
(months) M (SD)
15.4 (10.9) 14.1 (12.6) 1.01 (1.00 1.02) .013 1.02 (1.01 1.02) .001
Premature termination of treatment (%) Yes 128 (10.5) 503 (51.6) 0.11 (0.09 0.14) <.001 0.15 (0.12 0.19) <.001
No 1092 (89.5) 472 (48.4) Ref.
Time periods (%) 1 1999-2004 221 (18.1) 236 (24.2) 0.60 (0.46 0.77) <.001 0.51 (0.37 0.70) <.001
2 2005-2009 682 (55.9) 537 (55.1) 0.81 (0.66 1.00) .048 0.87 (0.68 1.12) .279
3 2010-2014 317 (26.0) 202 (20.7) Ref.
M mean, SD standard deviation
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has been suggested that the definition of recovery used in a
study has an important impact on outcome estimates [33].
In the present study, we refrained from defining recovery
and confined ourselves to only use the term “in remission”
for patients not fulfilling criteria for any ED diagnosis. It is
not possible either to make a full comparison of our results
with randomized controlled trials within this field (e.g. [15,
34–36]), due for instance to divergent study structures and
different ways of measuring outcome.
Approximately 70% of those who ended treatment
according to plan were rated as being in remission and
90% were within a healthy weight range. This indicates
the importance of completing treatment, which will be
discussed later on.
The results in the present study also show that remis-
sion rates and weight recovery increased over time, while
treatment duration decreased. The fact that patients over
the years became healthier when entering treatment is a
possible explanation. However, this cannot fully explain
these results since neither low weight nor complicating
factors at treatment onset was associated to a poor out-
come. The results might therefore indicate that treatment
has become more effective over the past 15 years. This
seems promising, but needs to be studied further since
there is not enough knowledge about causal factors and
the generalizability of such a trend.
The large number of patients within a healthy weight
range is, needless to say, a positive result. However, when
studying adolescents it is important to bear in mind that a
categorization in low and normal weight based on BMI isdifficult. Despite a BMI within a seemingly normal range,
a young patient may have a low weight or even be
underweight in relation to his or her own weight curve.
This information is unfortunately hard to capture within
SwEat, because of the large number of patients. A normal
weight does not necessarily mean that the patient is
healthy or recovered, and suffering from AN can be crit-
ical regardless of weight [2]. However, it is suggested in
previous studies that BMI is an important prognostic
factor [37] and that significant weight gain at EOT is a reli-
able predictor of recovery in adolescents with AN [38, 39].
Almost 60% of the adolescents had an AN diagnosis at
treatment onset, which in comparison to what is pre-
sented in previous studies is a fairly large proportion
[22, 40]. In these studies it is suggested that the majority
of adolescents seeking ED treatment have variants of
subthreshold diagnoses. Considering treatment outcome,
the results in our study did not show any differences be-
tween patients with AN or subthreshold AN. In fact, the
number of patients in remission did not differ at all
between the two groups. This corresponds to previous
results suggesting that patients with AN or subthreshold
AN in general suffer from symptoms to the same extent
[22–24], but runs counter to another study suggesting
that recovery is eight times more likely among patients
with subthreshold AN [41].
Patients in time period 2 and 3 were more often
considered to have a normal weight when entering
treatment, were less often diagnosed with AN, had
fewer experiences of previous ED treatment and less
social and psychiatric complicating factors. However,
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ment onset between the different time periods, as one
could expect. Instead, adolescents during later years
might have been seeking treatment for less serious
conditions, perhaps due to easier access to health care
and increased awareness of ED in society.
In our study, the average age when entering treatment
was 16.6 years, which is in accordance to results from a
British study suggesting that the peak age of presentation
for treatment is 15–19 years [5]. Age at first symptoms of
illness was on average 14.6 years, which indicates approxi-
mately two years of illness duration at treatment onset.
When excluding patients with experiences of previous ED
treatment, illness duration at treatment onset was slightly
shorter. In previous studies it is suggested that duration
between onset of illness and initiation of treatment is
often rather long, in particular when it comes to those
with an early onset of illness [7, 9]. This may partly reflect
the fact that many people with AN do not see their symp-
toms as problematic but more as a part of their identity
and that they lack internal motivation to recover [1, 7].
Many adolescents are likely to have atypical presentations
of ED, which increases the risk for delayed diagnoses and
significant complications [1, 2, 42, 43]. Approximately one
third of the patients in the present study terminated treat-
ment prematurely, either on their own or their parents’
initiative or due to referral to another treatment unit. This
corresponds to results from previous studies, suggesting a
proportion of 20–40% [11]. Premature termination of
treatment is considered a problem within several psychi-
atric disorders and in particular within the field of ED and
AN [44, 45]. For example, as this study also showed,
terminating treatment prematurely reduces the chance of
achieving remission while completing treatment increases
the chances of a good outcome [11, 35]. As mentioned
earlier, as many as 70% of those who ended treatment
according to plan were in remission and 90% within a
healthy weight range. Which clinical characteristics and
factors that can be associated with premature termination
have yet to be discovered, but one suggestion is dis-
crepancy between patient preferences and expectations
about treatment that may account for non-adherence
[1]. It may also be linked with treatment dissatisfac-
tion, which will be explored in an upcoming study
based on data from SwEat. In the present study, treat-
ment duration was approximately 15 months and it
has been suggested that treatment should last at least
six months for a desirable outcome [7, 20].
The fact that complicating social, psychiatric or somatic
factors were registered in more than one third of the
cases, of which most were psychiatric, is not surprising.
Although only a few studies have looked at social or
somatic factors (e.g. [46]), psychiatric comorbidity is
well known to be a complicating factor for thesepatients [4, 12, 41, 46]. For adolescents, psychiatric co-
morbidity comprises mainly mood- and anxiety disor-
ders, obsessive-compulsive disorder, substance abuse
and personality disorders [2, 4]. The results in the
present study indicate that psychiatric complications
might be associated with a poor outcome, which also
is in line with results from previous studies [46, 47].
For example, Wentz and colleagues found that psychiatric
complications might affect vulnerability for AN as well as
treatment outcome [46].
There are some limitations to this study. Considerable
attrition at follow-up in SwEat is one, over which we
unfortunately had no control when designing the study.
The amount of follow-up registrations in SwEat varies
greatly between different units, probably due to varying
follow-up procedures. In general, approximately 60% of
initial registrations were lost to follow-up one year later
[48], which might have to do with the fact that young
people often wish to terminate their treatment quickly.
The loss of patients at follow-up affects the generalizability
of the results, although we did not find any differences of
clinical relevance between followed-up and non-followed
up patients in the present study. Another limitation is the
missing data considering some of the variables in SwEat,
due for instance to different technical issues or errors when
registrations were made. As mentioned earlier, approxi-
mately 1–3% of the answers throughout the register are
missing or incorrect. The fact that height and weight in
some cases were self-reported by the patient might be
considered a limitation, although previous results suggest
that self-reported height and weight are reliable [49]. Some
major limitations to this study are that we had to judge the
reliability of what clinicians have reported for some of the
variables and that we, due to the many years examined and
the large amount of participating units, lacked control over
the assessments of symptoms and diagnoses. No inter-rater
agreement estimates were made and the procedure for es-
tablishing ED diagnoses varied over time as well as between
units in different parts of the country. Also, the fact that
some of the variables (e.g. age at first symptoms) were
assessed retrospectively may have led to memory bias.
These limitations, in addition to the fact that data might be
affected by selection bias, are related to the naturalistic
design of the study and mentioned also in previous studies
as disadvantages with naturalistic register studies [12, 50].
However, the design of the study also provides several
strengths. The large-scale naturalistic setting secures the
generalizability to a clinical environment and offers a
comparison for outcome data from treatment trials [20].
The naturalistic setting also provides a natural treatment
environment for patients and clinicians, when daily
routines can be followed despite study participation. An
additional strength with the present study is the number of
participating units, providing good national coverage.
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studies focusing on how different treatment settings and
approaches affect treatment outcome [51]. In recent
years several different methods have been examined and
tested, but nevertheless there are only a few uniform
recommendations that can be applied to patients of
different ages, with different diagnoses and in different
social situations. The most effective treatments for
adolescents with AN include family based therapy [52],
but it is important to take several aspects into consideration
when choosing a treatment model because of the hetero-
geneity of the patient group [53]. In the present study, no
distinction was made between specialist and non-specialist
ED units, but it has earlier been recommended that more
resources should be devoted to specialist outpatient
ED services with direct access from primary care for
better outcome [54].
Conclusions
Only a few naturalistic studies have focused on outcome
for patients in routine care. This study shows that approxi-
mately 55% were rated by clinicians as being in remission
and approximately 85% were rated as being within a
healthy weight range at EOT. The results indicate that
treatment for adolescents with ED in Sweden has become
more effective over the past 15 years, with more patients
reaching remission and a healthy weight after a shorter
treatment duration. The results of the present study
contribute to the scope of treatment research, but
more research is needed into different forms of evi-
dence, new research strategies and diversity of treat-
ment approaches.
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